176 related articles for article (PubMed ID: 25762479)
41. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma.
Pula B; Jethon A; Piotrowska A; Gomulkiewicz A; Owczarek T; Calik J; Wojnar A; Witkiewicz W; Rys J; Ugorski M; Dziegiel P; Podhorska-Okolow M
Histopathology; 2011 Dec; 59(6):1249-60. PubMed ID: 22175904
[TBL] [Abstract][Full Text] [Related]
42. Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.
Joseph C; Al-Izzi S; Alsaleem M; Kurozumi S; Toss MS; Arshad M; Goh FQ; Alshankyty IM; Aleskandarany MA; Ali S; Ellis IO; Mongan NP; Green AR; Rakha EA
Br J Cancer; 2019 Oct; 121(9):776-785. PubMed ID: 31558802
[TBL] [Abstract][Full Text] [Related]
43. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
44. Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer.
Ochnik AM; Baxter RC
BMC Cancer; 2017 Dec; 17(1):820. PubMed ID: 29207959
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
Kariri YA; Joseph C; Kurozumi S; Toss MS; Alsaleem M; Raafat S; Mongan NP; Aleskandarany MA; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jan; 179(2):349-357. PubMed ID: 31679074
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
Zhao P; Lu Y; Jiang X; Li X
Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
[TBL] [Abstract][Full Text] [Related]
47. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
49. Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node‑negative early breast cancer: 15-year follow-up.
Donizy P; Pietrzyk G; Halon A; Kozyra C; Gansukh T; Lage H; Surowiak P; Matkowski R
Oncol Rep; 2014 Apr; 31(4):1777-87. PubMed ID: 24535158
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of fatty acid binding protein-4 in the invasive ductal carcinoma of the breast.
Cui Y; Song M; Kim SY
Pathol Int; 2019 Feb; 69(2):68-75. PubMed ID: 30694572
[TBL] [Abstract][Full Text] [Related]
51. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
52. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
Wernicke AG; Varma S; Greenwood EA; Christos PJ; Chao KS; Liu H; Bander NH; Shin SJ
APMIS; 2014 Jun; 122(6):482-9. PubMed ID: 24304465
[TBL] [Abstract][Full Text] [Related]
53. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters.
Lee WY; Jin YT; Chang TW; Lin PW; Su IJ
Histopathology; 1999 Feb; 34(2):106-12. PubMed ID: 10064388
[TBL] [Abstract][Full Text] [Related]
54. COX2 overexpression is a prognostic marker for Stage III breast cancer.
Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
[TBL] [Abstract][Full Text] [Related]
55. LETM1 overexpression is correlated with the clinical features and survival outcome of breast cancer.
Li N; Zheng Y; Xuan C; Lin Z; Piao L; Liu S
Int J Clin Exp Pathol; 2015; 8(10):12893-900. PubMed ID: 26722481
[TBL] [Abstract][Full Text] [Related]
56. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
Joseph C; Alsaleem M; Orah N; Narasimha PL; Miligy IM; Kurozumi S; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jul; 182(2):267-282. PubMed ID: 32445177
[TBL] [Abstract][Full Text] [Related]
57. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.
Pan D; Kocherginsky M; Conzen SD
Cancer Res; 2011 Oct; 71(20):6360-70. PubMed ID: 21868756
[TBL] [Abstract][Full Text] [Related]
58. Higher levels of GATA3 predict better survival in women with breast cancer.
Yoon NK; Maresh EL; Shen D; Elshimali Y; Apple S; Horvath S; Mah V; Bose S; Chia D; Chang HR; Goodglick L
Hum Pathol; 2010 Dec; 41(12):1794-801. PubMed ID: 21078439
[TBL] [Abstract][Full Text] [Related]
59. The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer.
Cheng KK; Dickson A; Gujam FJ; McMillan DC; Edwards J
Histopathology; 2017 Apr; 70(5):782-797. PubMed ID: 27891654
[TBL] [Abstract][Full Text] [Related]
60. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
